Adverum Biotechnologies (ADVM)

• Market cap: $57M
• 1 day: -6.83%
• 5 days: -20.41%
• 1 month: -46.47%
• 3 months: -37.95%
• 6 months: -66.95%
• Year to date: -43.12%
• 1 year: -75.93%
• 5 years: -97.80%
• 10 years: -99.31%
• Sector: Healthcare
• Industry: Biotechnology

About: Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.

Employees: 155

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

125% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 12

100% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 4 (+2) [Q4]

5.13% less ownership

Funds ownership: 81.45% [Q3] → 76.32% (-5.13%) [Q4]

9% less funds holding

Funds holding: 76 [Q3] → 69 (-7) [Q4]

27% less call options, than puts

Call options by funds: $45K | Put options by funds: $62K

38% less capital invested

Capital invested by funds: $120M [Q3] → $74.1M (-$46M) [Q4]

44% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 16

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $5 83% upside
• Avg. target: $23 730% upside
• High target: $33 1,109% upside

3 analyst ratings

• positive: 2 67%
• neutral: 1 33%
• negative: 0 0%

Chardan Capital Daniil Gataulin 16% 1-year accuracy 8 / 49 met price target	1,109% upside $33	Buy Maintained	17 Apr 2025
RBC Capital Luca Issi 6% 1-year accuracy 3 / 54 met price target	83% upside $5	Sector Perform Maintained	16 Apr 2025
HC Wainwright & Co. Matthew Caufield 22% 1-year accuracy 15 / 68 met price target	999% upside $30	Buy Reiterated	16 Apr 2025